Cara Therapeutics, Inc. (CARA Quick QuoteCARA - Free Report) was a big mover last session, as the company saw its shares rise over 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend  for the company—as the stock is now up 53.5% in the past one-month time frame.

The move came after Cara's lead drug candidate received FDA breakthrough-therapy status for use in patients with kidney disease.

The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Cara Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Cara Therapeutics, Inc. Price

Cara Therapeutics, Inc. Price | Cara Therapeutics, Inc. Quote

Investors interested in the Medical - Biomedical and Geneticsindustry may consider a better-ranked stock like Exelixis, Inc.,(EXEL Quick QuoteEXEL - Free Report) which carries a Zacks Rank #1 (Strong Buy).

Is CARA going up? Or down? Predict to see what others think: Up or Down

Sell These Stocks. Now

Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. 

See today's Zacks ""Strong Sells"" absolutely free >>